Salarius Pharmaceuticals Inc (NASDAQ:SLRX)’s traded shares stood at 2.23 million during the last session, with the company’s beta value hitting 0.81. At the close of trading, the stock’s price was $2.62, to imply an increase of 3.97% or $0.1 in intraday trading. The SLRX share’s 52-week high remains $7.20, putting it -174.81% down since that peak but still an impressive 53.44% since price per share fell to its 52-week low of $1.22. The company has a valuation of $3.77M, with an average of 12.35 million shares in intraday trading volume over the past 10 days and average of 2.19 million shares over the past 3 months.
Salarius Pharmaceuticals Inc (NASDAQ:SLRX) trade information
After registering a 3.97% upside in the last session, Salarius Pharmaceuticals Inc (SLRX) has traded red over the past five days. The 5-day price performance for the stock is 60.74%, and 78.24% over 30 days. With these gigs, the year-to-date price performance is 42.39%. Short interest in Salarius Pharmaceuticals Inc (NASDAQ:SLRX) saw shorts transact 65040.0 shares and set a 0.08 days time to cover.
SLRX Dividends
Salarius Pharmaceuticals Inc has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Salarius Pharmaceuticals Inc (NASDAQ:SLRX)’s Major holders
Salarius Pharmaceuticals Inc insiders hold 2.52% of total outstanding shares, with institutional holders owning 0.36% of the shares at 0.37% float percentage. In total, 0.36% institutions holds shares in the company.
We also have Fidelity Extended Market Index Fund and Listed Funds Tr-Horizon Kinetics Medical ETF as the top two Mutual Funds with the largest holdings of the Salarius Pharmaceuticals Inc (SLRX) shares. Going by data provided on Nov 30, 2024 , Fidelity Extended Market Index Fund holds roughly 5.74 shares. This is just over 0.40% of the total shares, with a market valuation of $15033.0. Data from the same date shows that the other fund manager holds a little less at 3.72, or 0.26% of the shares, all valued at about 9754.0.
